Fragile X Syndrome Test at Chughtai Lab

Fragile X Syndrome Test at Chughtai Lab

Fragile X Syndrome (FXS) is a genetic condition characterized by mild-to-moderate intellectual disability, developmental delays, behavioral challenges, and distinctive physical features. It is the most common inherited cause of intellectual disability and the most common known single-gene cause of autism spectrum disorder. The Fragile X Syndrome (From Outsource UK) test offered at Chughtai Lab is a highly specialized molecular diagnostic assay designed to analyze the FMR1 (Fragile X Mental Retardation 1) gene located on the X chromosome. This test is crucial for diagnosing individuals with clinical symptoms of FXS, identifying carriers, and assisting in prenatal and family planning decisions. By partnering with leading international reference laboratories in the United Kingdom, Chughtai Lab ensures that patients in Pakistan have access to gold-standard genetic testing utilizing advanced molecular techniques such as Polymerase Chain Reaction (PCR) and Southern Blot analysis.

The FMR1 gene normally contains a segment of DNA known as a CGG trinucleotide repeat, which repeats a specific number of times. In individuals with Fragile X Syndrome, this CGG segment is abnormally expanded, leading to the silencing of the FMR1 gene and the subsequent loss of the Fragile X Mental Retardation Protein (FMRP). FMRP is essential for normal brain development, synaptic plasticity, and cognitive function. The molecular analysis performed through this outsourced test precisely quantifies the number of CGG repeats, classifying individuals into normal, intermediate (gray zone), premutation, or full mutation categories. Understanding these genetic variations is vital for clinical management, prognosis, and genetic counseling.

Clinical Procedure: What to Expect

Patient Preparation

Proper preparation is essential to ensure sample integrity and accurate molecular analysis. Patients undergoing the Fragile X Syndrome test should observe the following guidelines:

• No Fasting Required: Fasting is not necessary for this molecular genetic test. Patients may eat and drink normally prior to sample collection.
• Medication Continuity: Regular medications can be continued as prescribed by your physician. There are no specific pharmacological restrictions.
• Genetic Counseling: It is highly recommended that patients and families undergo pre-test genetic counseling to understand the implications of potential results, inheritance patterns, and the impact on family members.
• Documentation: Ensure that all clinical referral forms, family history documents, and consent forms are accurately completed and submitted at the time of sample collection.

During the Procedure

The collection of the biological sample for the Fragile X Syndrome test is a straightforward and safe procedure. The process is conducted as follows:

• Patient Positioning: The patient is comfortably seated. For infants or young children, a parent or guardian may hold them securely to ensure safety during the blood draw.
• Venipuncture Process: A trained phlebotomist at Chughtai Lab cleans the skin over a vein, typically in the inner elbow, with an antiseptic solution. A sterile needle is inserted to collect a whole blood sample into an EDTA tube.
• Sample Volume: A standard volume of blood (approximately 3 to 5 mL) is collected. For pediatric patients, smaller volumes appropriate for age and weight are obtained.
• Safety and Comfort: The procedure takes only a few minutes. Mild, temporary discomfort or bruising at the puncture site may occur, which is normal and resolves quickly.
• Sample Processing: Once collected, the sample is carefully labeled, documented, and prepared for secure international transport to the partner reference laboratory in the United Kingdom under strict temperature-controlled conditions to preserve DNA quality.

When is a Fragile X Syndrome Test Performed?

Developmental Delay and Intellectual Disability

Physicians request this test for infants and children presenting with unexplained developmental delays, particularly in speech and motor skills, or intellectual disabilities. Identifying the genetic cause helps pediatricians and developmental specialists tailor educational and therapeutic interventions early in life.

Autism Spectrum Disorder and Behavioral Challenges

Since Fragile X Syndrome is the leading single-gene cause of autism, children diagnosed with autism spectrum disorder, severe attention deficit hyperactivity disorder (ADHD), social anxiety, or hand-flapping behaviors are routinely screened for the FMR1 gene expansion to confirm or rule out FXS.

Premature Ovarian Insufficiency

Women experiencing irregular menstrual cycles, infertility, or elevated follicle-stimulating hormone (FSH) levels before the age of 40 may carry the FMR1 premutation. This condition, known as Fragile X-Associated Premature Ovarian Insufficiency (FXPOI), is diagnosed through this targeted genetic analysis.

Late-Onset Tremor and Ataxia

Older adults, particularly males over the age of 50 presenting with progressive intention tremors, cerebellar ataxia, cognitive decline, or parkinsonism, may be evaluated for Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS), which is caused by the FMR1 premutation.

Family History and Carrier Screening

Individuals with a known family history of Fragile X Syndrome, unexplained intellectual disability, or developmental delays often undergo carrier screening. This is particularly important for women planning a pregnancy, as carriers have an increased risk of passing the expanded gene to their offspring.

What Does a Fragile X Syndrome Test Detect?

The Fragile X Syndrome molecular test is designed to detect and analyze several critical genetic parameters, including:

• Normal CGG repeat range (typically 5 to 44 repeats)
• Intermediate or “gray zone” CGG repeat range (typically 45 to 54 repeats)
• Premutation CGG repeat range (typically 55 to 200 repeats)
• Full mutation CGG repeat range (greater than 200 repeats)
• FMR1 gene hypermethylation status
• Transcriptional silencing of the FMR1 gene
• Absence or reduction of Fragile X Mental Retardation Protein (FMRP) expression
• Female carrier status for Fragile X Syndrome
• Male transmission risk of the premutation to daughters
• Risk of expansion of premutation to full mutation in maternal transmission
• Genetic etiology of unexplained intellectual disability
• Genetic etiology of autism spectrum disorder
• Diagnosis of Fragile X-Associated Premature Ovarian Insufficiency (FXPOI)
• Diagnosis of Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS)
• FMR1 gene mosaicism (size or methylation mosaicism)
• X-linked dominant inheritance patterns
• Risk assessment for future pregnancies
• Identification of asymptomatic carriers within a family
• Clarification of borderline or ambiguous genetic results
• Guidance for early intervention and educational support
• Determination of eligibility for clinical trials or targeted therapies
• Differentiation from other syndromic causes of developmental delay
• Confirmation of clinical diagnosis in symptomatic males
• Confirmation of clinical diagnosis in symptomatic females
• Assessment of ovarian reserve risk in female carriers

Turnaround Time and Report Access at Chughtai Lab

Because the Fragile X Syndrome (From Outsource UK) test requires highly specialized molecular analysis, the sample is securely transported to our partner reference laboratory in the United Kingdom. The typical turnaround time for this advanced genetic test is approximately 3 to 4 weeks. Once the comprehensive clinical report is finalized and verified by consultant geneticists, it is uploaded directly to the Chughtai Lab online portal. Patients and referring physicians can access and download the report securely via the Chughtai Lab mobile application or the official website. Hard copies of the report can also be collected from any Chughtai Lab diagnostic center across Pakistan.

Fragile X Syndrome Test Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
CGG Repeat Count (FMR1 Gene)	5 to 44 repeats	45-54 (Intermediate), 55-200 (Premutation), >200 (Full Mutation)
FMR1 Methylation Status	Unmethylated promoter region	Hypermethylated promoter region (associated with full mutation)
FMRP Expression	Normal levels of Fragile X Mental Retardation Protein	Absent or severely reduced FMRP levels
Clinical Status (Male)	Unaffected, typical cognitive development	Fragile X Syndrome (intellectual disability, dysmorphic features) or FXTAS
Clinical Status (Female)	Unaffected, typical development	Variable presentation (mild learning disabilities, FXPOI, or FXTAS)
Offspring Transmission Risk (Male)	No elevated risk	Transmits premutation to all daughters; 0% risk of transmitting full mutation
Offspring Transmission Risk (Female)	No elevated risk	Up to 50% risk of transmitting an expanded allele (premutation can expand to full mutation)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for Fragile X Syndrome Test?

• International Quality Standards: Collaboration with premier reference laboratories in the United Kingdom ensures international-grade molecular testing accuracy.
• Advanced Molecular Technology: Utilization of high-resolution PCR and Southern Blot analysis for precise CGG repeat quantification.
• Secure Cold-Chain Logistics: Specialized specimen preservation and transport protocols maintain sample integrity from Pakistan to the UK.
• Nationwide Accessibility: Convenient sample collection available at numerous Chughtai Lab centers across Pakistan.
• Highly Trained Phlebotomists: Professional and gentle blood collection services, particularly experienced with pediatric patients.
• Digital Report Access: Secure and immediate access to genetic reports via the Chughtai Lab mobile app and online portal.
• Confidentiality and Security: Strict adherence to patient data privacy regulations for sensitive genetic information.
• Comprehensive Diagnostic Portfolio: A wide range of supporting laboratory investigations to assist in multi-disciplinary clinical management.